Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.
A 16-amino-acid peptide encoded in mitochondrial DNA, studied in relation to metabolism and insulin sensitivity. Human clinical data is limited.
Carries the strongest 'GLP-1-adjacent' metabolic and longevity narrative, which drives search interest. Reviewed at the FDA July 2026 meeting.
| Claim | Strongest evidence |
|---|---|
| Metabolism / insulin sensitivity | C Animal |
| Obesity | R Regulatory only |
| Longevity | D Cell / mechanistic |
FDA said the nomination lacked sufficient information for several uses and did not identify clinical studies evaluating them; staff proposed not adding it.
No robust human trials for the marketed uses. Longevity claims rest on mechanistic/animal reasoning, not human outcomes.
No. GLP-1 drugs are approved medicines with large trials; MOTS-c is experimental with limited human data.
One email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.
Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.